Person: TRUE, ÖMER
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
TRUE
First Name
ÖMER
Name
5 results
Search Results
Now showing 1 - 5 of 5
Publication Metadata only Akut lenfoblastik lösemili düşük ve orta gelirli çocukların tedavisinde değiştirilmiş jude total therapy XV protokolünün sonuçları: marmara deneyimi(2022-05-25) KOÇ, AHMET; TRUE, ÖMER; Yılmaz B., Koç A., Doğru Ö., Taş B. T. , Şenay R. E.Publication Open Access Successful treatment of refractory graft-versus-host disease with ruxolitinib in a child after autologous stem cell transplantation(2022-06-01) TRUE, ÖMER; TOKUÇ, AYŞE GÜLNUR; KOÇ, AHMET; EKER, NURŞAH; Eker N., Tas B. T., Doğru Ö., Senay E., Tokuç A. G., Koç A.Autologous hematopoietic stem cell transplantation (AHSCT) is an increasingly used curative treatment for some solid tumors in children. Instead of allogeneic transplantation, the risk of developing graft-versus-host disease (GvHD) is much lower after AHSCT. Although the clinical findings of auto-GVHD are mild and self-limited in most cases, rare cases may be severe and need intensive immunosuppressive treatment. Here, we present a case who underwent autologous HSCT due to relapsed neuroblastoma, developed steroid-refractory GvHD after AHSCT, and achieved remission using ruxolitinib. A 12 years old female patient was diagnosed with relapsed neuroblastoma. After metaiodobenzylguanidine treatment, AHSCT was performed, and the status of the disease was a very good partial response at the time of transplantation. Our patient was diagnosed with severe and steroid-refractory GvHD with skin involvement after AHSCT. We used ruxolitinib with extracorporeal photopheresis because of the essential side effects of the other drugs and got a very good response. Over the following five months, there was no recurrence of GvHD. She was in complete remission of neuroblastoma after two years of AHSCT. It is crucial to keep in mind that GvHD may develop after AHSCT. Ruxolitinib is an effective treatment for GvHD also after AHSCT. Further studies and case reports are needed to understand the disease\"s pathogenesis and regulate appropriate treatment.Publication Metadata only Griscelli Sendromuna Bağlı Gelişen Refrakter Hemofagositik Lenfohistiosiz Tedavisinde Ruksolitinib’in Yeri(2023-05-26) KOÇ, AHMET; TRUE, ÖMER; AYDINER, ELİF; Şenay R. E., Koç A., Doğru Ö., Dinç O., Aydıner E.Publication Metadata only Malignancy and lymphoid proliferation in primary immune deficiencies; hard to define, hard to treat(WILEY, 2020) KOÇ, AHMET; Kiykim, Ayca; Eker, Nursah; Surekli, Ozlem; Nain, Ercan; Kasap, Nurhan; Akturk, Hacer; Dogru, Omer; Canbolat, Aylin; Somer, Ayper; Koc, Ahmet; Tokuc, Gulnur; Bozkurt, Suheyla; Turkoz, Kemal; Karakoc-Aydiner, Elif; Ozen, Ahmet; Baris, SafaBackground Regarding the difficulties in recognition and management of the malignancies in primary immune deficiencies (PIDs), we aimed to present the types, risk factors, treatment options, and prognosis of the cancers in this specific group. Methods Seventeen patients with PID who developed malignancies or malignant-like diseases were evaluated for demographics, clinical features, treatment, toxicity, and prognosis. Results The median age of malignancy was 12.2 years (range, 2.2-26). Lymphoma was the most frequent malignancy (n = 7), followed by adenocarcinoma (n = 3), squamous cell carcinoma (n = 2), cholangiocarcinoma (n = 1), Wilms tumor (n = 1), and acute myeloid leukemia (n = 1). Nonneoplastic lymphoproliferation mimicking lymphoma was observed in five patients. The total overall survival (OS) was 62.5% +/- 12.1%. The OS for lymphoma was 62.2% +/- 17.1% and found to be inferior to non-PID patients with lymphoma (P = 0.001). Conclusion In patients with PIDs, malignancy may occur and negatively affect the OS. The diagnosis can be challenging in the presence of nonneoplastic lymphoproliferative disease or bone marrow abnormalities. Awareness of susceptibility to malignant transformation and early diagnosis with multidisciplinary approach can save the patients' lives.Publication Open Access Hematopoietic stem cell transplantation to a patient with acute myeloid leukemia from a sibling donor positive for SARS-CoV-2 by RT-PCR test(2022-01-01) KOÇ, AHMET; TRUE, ÖMER; EKER, NURŞAH; KOÇ A., DOĞRU Ö., EKER N., Tas B. T., Senay R. E.